Dr. Andrew Poklepovic, MD
Claim this profileVirginia Commonwealth University/Massey Cancer Center
Expert in Cancer
Expert in Tumors
33 reported clinical trials
82 drugs studied
Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage I
2Tumors
Global LeaderStage IV
RAS positive
EGFR positive
Affiliated Hospitals
Clinical Trials Andrew Poklepovic, MD is currently running
Cemiplimab + Palbociclib
for Liposarcoma
This phase II trial compares the effect of treatment with palbociclib alone to treatment with palbociclib plus cemiplimab for treating patients with dedifferentiated liposarcoma that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Palbociclib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Cemiplimab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. The combination of these two drugs may be more effective in shrinking or stabilizing advanced dedifferentiated liposarcoma compared to palbociclib alone.
Recruiting1 award Phase 2
Nivolumab + Ipilimumab + Sargramostim
for Advanced Melanoma
This phase II/III trial studies the side effects of nivolumab and ipilimumab when given together with or without sargramostim and to see how well they work in treating patients with stage III-IV melanoma that cannot be removed by surgery (unresectable) and that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Colony-stimulating factors, such as sargramostim, may increase the production of white blood cells. It is not yet known whether nivolumab and ipilimumab are more effective with or without sargramostim in treating patients with melanoma.
Recruiting1 award Phase 2 & 323 criteria
More about Andrew Poklepovic, MD
Clinical Trial Related4 years of experience running clinical trials · Led 33 trials as a Principal Investigator · 13 Active Clinical TrialsTreatments Andrew Poklepovic, MD has experience with
- Nivolumab
- Biospecimen Collection
- Pembrolizumab
- Ipilimumab
- Paclitaxel
- Ipatasertib
Breakdown of trials Andrew Poklepovic, MD has run
Cancer
Tumors
Melanoma
Skin Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Andrew Poklepovic, MD specialize in?
Andrew Poklepovic, MD focuses on Cancer and Tumors. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are Stage III.
Is Andrew Poklepovic, MD currently recruiting for clinical trials?
Yes, Andrew Poklepovic, MD is currently recruiting for 11 clinical trials in Richmond Virginia. If you're interested in participating, you should apply.
Are there any treatments that Andrew Poklepovic, MD has studied deeply?
Yes, Andrew Poklepovic, MD has studied treatments such as Nivolumab, Biospecimen Collection, Pembrolizumab.
What is the best way to schedule an appointment with Andrew Poklepovic, MD?
Apply for one of the trials that Andrew Poklepovic, MD is conducting.
What is the office address of Andrew Poklepovic, MD?
The office of Andrew Poklepovic, MD is located at: Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia 23298 United States. This is the address for their practice at the Virginia Commonwealth University/Massey Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.